Table 3.
The results of subgroup analysis for serum TC, TG, HDL-C, LDL-C, AST, and ALT.
| Subgroup | Study | WMD (95% CI) | P value | Heterogeneity (I2) | Meta-regression | Test of group differences P > Q_b | |
|---|---|---|---|---|---|---|---|
| TG | |||||||
| Age | ≥50 years old | 3 | −2.76 (−28.35, 22.83) | 0.83 | 0.0 | — | 0.718 |
| <50 years old | 6 | −7.93 (−19.36, 3.5) | 0.17 | 3.7 | |||
| Duration | ≤12 weeks | 4 | −5.47 (−16.48, 5.55) | 0.33 | 0.0 | — | 0.373 |
| >12 weeks | 5 | −21.10 (−17.51, 3.37) | 0.20 | 0.0 | |||
| Baseline BMI | >30 | 4 | −7.31 (−18.72, 4.10) | 0.21 | 0.0 | — | 0.920 |
| <30 | 4 | −5.86 (−31.57, 19.85) | 0.65 | 0.0 | |||
| Baseline body weight | >85 kg | 4 | −7.31 (−18.72, 4.10) | 0.21 | 0.0 | — | 0.920 |
| <85 kg | 4 | −5.86 (−31.57, 19.85) | 0.65 | 0.0 | |||
| Intervention type | GLP-1 agonists | 8 | −11.96 (−32.24, 8.32) | 0.24 | 0.0 | — | 0.582 |
| GLP-1 agonists + other treatment | 1 | −5.31 (−17.48, 6.86) | 0.39 | — | |||
|
| |||||||
| TC | |||||||
| Age | ≥50−years old | 3 | −0.17 (−6.95, 6.61) | 0.96 | 0.0 | — | 0.719 |
| <50 years old | 6 | −1.73 (−6.84, 3.37) | 0.50 | 51.9 | |||
| Duration | ≤12 weeks | 4 | −2.93 (−7.74, 1.88) | 0.23 | 52.1 | — | 0.175 |
| >12 weeks | 5 | 3.35 (−4.34, 11.05) | 0.39 | 0.0 | |||
| Baseline BMI | >30 | 4 | −3.39 (−9.00, 2.21) | 0.23 | 51.0 | — | 0.256 |
| <30 | 4 | 1.33 (−4.61, 7.28) | 0.65 | 0.0 | |||
| Baseline body weight | >85 kg | 4 | −3.39 (−9.00, 2.21) | 0.23 | 51.0 | — | 0.256 |
| <85 kg | 4 | 1.33 (−4.61, 7.28) | 0.65 | 0.0 | |||
| Intervention type | GLP-1 agonists | 8 | −0.95 (−6.08, 4.18) | 0.71 | 36.2 | — | 0.891 |
| GLP-1 agonists + other treatment | 1 | −1.54 (−8.27, 5.19) | — | — | |||
|
| |||||||
| HDL-C | |||||||
| Age | ≥50 years old | 3 | 2.84 (−0.18, 5.86) | 0.06 | 0.0 | — | 0.307 |
| <50 years old | 5 | 0.40 (−3.18, 3.98) | 0.82 | 55.8 | |||
| Duration | ≤12 weeks | 3 | 2.43 (−0.76, 5.63) | 0.13 | 0.0 | — | 0.460 |
| >12 weeks | 5 | 0.56 (−3.21, 4.35) | 0.76 | 61.8 | |||
| Baseline BMI | >30 | 4 | 1.61 (−3.03, 6.26) | 0.49 | 76.1 | — | 0.619 |
| <30 | 4 | 0.16 (−3.17, 3.50) | 0.92 | 0.0 | |||
| Baseline body weight | >85 kg | 4 | 1.61 (−3.03, 6.26) | 0.49 | 76.1 | — | 0.619 |
| <85 kg | 4 | 0.16 (−3.17, 3.50) | 0.92 | 0.0 | |||
|
| |||||||
| LDL-C | |||||||
| Age | ≥50 years old | 3 | −1.02 (−7.17, 5.12) | 0.74 | 0.0 | 0.45 (−1.87, 2.78) | 0.890 |
| <50 years old | 5 | −2.22 (−18.06, 13.60) | 0.78 | 81.8 | |||
| Duration | ≤12 weeks | 3 | −9.48 (−24.70, 5.74) | 0.22 | 83.8 | 0.36 (−0.37, 1.40) | 0.097 |
| >12 weeks | 5 | 4.79 (−2.48, 12.07) | 0.19 | 5.8 | |||
| Baseline BMI | >30 | 4 | −8.96 (−24.42, 6.50) | 0.25 | 71.9 | −3.43 (−7.10, 0.22) | 0.155 |
| <30 | 4 | 3.26 (−3.46, 10.00) | 0.34 | 30.3 | |||
| Baseline body weight | >85 kg | 4 | −8.96 (−24.42, 6.50) | 0.25 | 71.9 | −0.59 (−1.36, 0.18) | |
| <85 kg | 4 | 3.26 (−3.46, 10.00) | 0.34 | 30.3 | |||
|
| |||||||
| AST | |||||||
| Age | ≥50 years old | 4 | −5.04 (−11.24, 1.15) | 0.11 | 95.2 | −0.31 (−1.22, 0.58) | 0.663 |
| <50 years old | 8 | −1.60 (−8.97, 5.77) | 0.67 | 80.4 | |||
| Duration | ≤12 weeks | 5 | −8.07 (−13.86, −2.29) | 0.006 | 94.4 | 0.36 (−0.22, 0.95) | 0.031 |
| >12 weeks | 7 | 1.84 (−1.59, 5.28) | 0.29 | 0.2 | |||
| Intervention type | GLP-1 agonists | 10 | −0.35 (−3.44, 2.75) | 0.82 | 47.6 | — | 0.000 |
| GLP-1 agonists + other treatment | 2 | −10.81 (−13.03, −8.59) | <0.001 | 14.7 | |||
|
| |||||||
| ALT | |||||||
| Age | ≥50 years old | 4 | −10.71 (−15.32, −6.11) | <0.001 | 71.1 | −0.30 (−1.86, 1.26) | 0.997 |
| <50 years old | 8 | −8.47 (−22.18, 5.24) | 0.22 | 88.1 | |||
| Duration | ≤12 weeks | 5 | −18.12 (−27.34, −8.91) | <0.001 | 94.2 | 0.53 (−0.41, 1.48) | 0.003 |
| >12 weeks | 7 | −2.05 (−8.43, 4.31) | 0.52 | 20.7 | |||
| Intervention type | GLP-1 agonists | 10 | −7.69 (−14.20, −1.18) | 0.02 | 64.7 | — | 0.378 |
| GLP-1 agonists + other treatment | 2 | −18.40 (−41.32, 4.52) | 0.11 | 96.6 | |||